Resolving intestinal fibrosis through regenerative medicine

Curr Opin Pharmacol. 2019 Dec:49:90-94. doi: 10.1016/j.coph.2019.09.011. Epub 2019 Nov 2.

Abstract

Crohn's Disease and Ulcerative Colitis, known collectively as Inflammatory Bowel Disease (IBD), are lifelong gastrointestinal disorders that commonly present at a young age and are increasing in incidence and prevalence. Fibrosis is a common and incurable complication of IBD. When fibrotic complications occur, patients often have to undergo disfiguring surgery. Thus, research has focused on regenerative therapies as a means to prevent and treat established fibrosis. Both cell and non-cell therapies (exosomes) have anti-fibrotic and anti-inflammatory properties. This review discusses these emerging therapeutics and their potential to treat intestinal fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Exosomes
  • Fibrosis
  • Humans
  • Intestinal Diseases / therapy*
  • Intestines / pathology*